摘要
目的:观察中药癌理通外敷联合奥施康定口服治疗中、重度肝区癌痛的临床疗效。方法:采用分组随机化、双盲、平行、对照临床试验方案,将78例患者分为治疗组和对照组各39例。治疗组予癌理通外敷联合奥施康定治疗,对照组予安慰剂外敷联合奥施康定治疗。比较2组镇痛疗效、所需奥施康定用量及不良反应发生情况。结果:平均镇痛起效时间治疗组为45.7min,对照组为47.3min。2组比较,差异无显著性意义(P>0.05)。但镇痛维持时间治疗组为(13.65±1.73)h,对照组为(11.37±2.04)h,2组比较,差异有非常显著性意义(P<0.01)。2组各程度疼痛缓解率比较,差异无显著性意义(P>0.05)。治疗组所需奥施康定用量较对照组明显减少,2组比较,差异有非常显著性意义(P<0.01)。2组不良反应发生率比较,差异无显著性意义(P>0.05)。结论:癌理通外敷治疗中、重度肝区癌痛可以增加奥施康定镇痛的维持时间,减少奥施康定的使用剂量,对镇痛早期难以耐受奥施康定恶心呕吐不良反应,具有增效减毒作用。
Objective:To observe the therapeutic effect of external application of Ailitong combined with oxycontin for moderate-severe carcinomatous pain over hepatic region.Methods:A block-randomized,double-blind,parallel and controlled trial was carried out in 78 patients with moderate-severe carcinomatous pain over hepatic region,The patients were randomized into 2 groups:the treatment group received external application of Ailitong combined with oxycontin,and the control group received external application of placebo combined with oxycontin.After treat- ment,effect on relieving pain,oxycontin dosage and adverse reaction in the two groups were com- pared.Results:The initial time for analgesia was 45.7 min in the treatment group and 47.3 min in the control group,the difference was insignificant between the two groups (P>0.05).But the lasting time for analgesia in the treatment group (13.65±1.73 hours) differed from that (11.37±2.04 hours) in the control group (P<0.01).The difference of pain-relieving rate was significant between the two groups(P<0.05).The oxycontin dosage was obviously decreased in the treatment group (P<0.01 compared with the control group).The difference of incidence of adverse reaction was insignificant between the two group.(P>0.05).Conclusion:External application of Ailitong can prolong the analgesic lasting time in the treatment of moderate-severe carcinomatous pain over hepatic region with oxycontin,and decrease the dusage of oxycontin,which will he practical for the patients having obvious adverse reaction of oxycontin.
出处
《新中医》
CAS
北大核心
2009年第2期24-25,共2页
New Chinese Medicine
基金
广东省科技厅科研课题(编号:2005B36001012)
